GLPwatch
Papers (10404)
Page 88 of 174, ranked by citation count.
- Effects of Glucagon-Like Peptide-1 receptor agonists on bone health in people living with obesity.
- In vitro comparison of various antioxidants and flavonoids from Rooibos as beta cell protectants against lipotoxicity and oxidative stress-induced cell death.
- Glycemia and Gluconeogenesis With Metformin and Liraglutide: A Randomized Trial in Youth-onset Type 2 Diabetes.
- Ease-of-use and acceptability of the novel semaglutide 2.4 mg single-dose pen-injector in people with overweight or obesity in the STEP 8 phase III trial.
- Liraglutide Therapy in a Prediabetic State: Rethinking the Evidence.
- Appetite suppressant semaglutide is to be made available to treat obesity in England.
- Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.
- Semaglutide and effective weight control.
- Liraglutide on type 2 diabetes mellitus with nonalcoholic fatty liver disease: A systematic review and meta-analysis of 16 RCTs.
- Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial.
- Role of exendin-4 in the Gila monster: Further lessons regarding human oral glucagon-like peptide-1 therapy?
- Oral Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes. Reply.
- Comparing the effects of empagliflozin and liraglutide on lipid metabolism and intestinal microflora in diabetic mice.
- Semaglultide targets Spp1<sup>+</sup> microglia/macrophage to attenuate neuroinflammation following perioperative stroke.
- Semaglutide suppresses cocaine taking, seeking, and cocaine-evoked dopamine levels in the nucleus accumbens.
- Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial.
- Worth Their Weight? An Update on New and Emerging Pharmacologic Agents for Obesity and Their Potential Role for Persons with Cardiac Conditions.
- Comparison of glucose control by added liraglutide to only insulin infusion in diabetic patient undergoing cardiac surgery: A preliminary randomized-controlled trial.
- Effects of exenatide on urinary albumin in overweight/obese patients with T2DM: a randomized clinical trial.
- Impact of semaglutide on lipid profiles in overweight and obese non-diabetic adults: A systematic review and meta-analysis of randomized controlled trials.
- Once-Weekly Dulaglutide with Insulin Therapy for Type 2 Diabetes: Efficacy and Safety Results from a Phase 4, Randomized, Placebo-Controlled Study.
- Diabetic Ketoacidosis in a Patient With Type I Diabetes Treated With a Closed-Loop Sensor-Augmented Insulin Infusion System.
- Semaglutide and cardiovascular outcomes by baseline HbA1c in diabetes: the SUSTAIN 6 and PIONEER 6 trials.
- Ceramides are decreased after liraglutide treatment in people with type 2 diabetes: a post hoc analysis of two randomized clinical trials.
- Dulaglutide accelerates diabetic wound healing by suppressing Nrf2-dependent ferroptosis in diabetic mice.
- Managing bile acid diarrhea: aspects of contention.
- The influence of anti-hyperglycemic drug therapy on cardiovascular and heart failure outcomes in patients with type 2 diabetes mellitus.
- A Cross-Species Atlas of the Dorsal Vagal Complex Reveals Neural Mediators of Cagrilintide's Effects on Energy Balance.
- A new era in the management of type 2 diabetes: Is cardioprotection at long last a reality?
- Late and severe acute necrotizing pancreatitis in a patient with liraglutide.
- Real-World Weight Loss Observed With Semaglutide and Tirzepatide in Patients with Overweight or Obesity and Without Type 2 Diabetes (SHAPE).
- Mitigation of Hearing Damage After Repeated Blast Exposures in Animal Model of Chinchilla.
- Glucagon-like peptide-1 receptor controls exocytosis in chromaffin cells by increasing full-fusion events.
- [Regulatory effect of liraglutide on the expression of eNOS in the corpus cavernosum of diabetic rats].
- Cardiovascular Effects of Liraglutide.
- Liraglutide: a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes mellitus.
- Maladaptive Eating Behaviours, Generalised Anxiety Disorder and Depression Severity: A Comparative Study between Adult Women with Overweight, Obesity, and Normal Body Mass Index Range.
- Optimizing outcomes for GLP-1 agonists.
- Evidence for pathophysiological commonalities between metabolic and neurodegenerative diseases.
- Anaphylaxis to Long-Acting Release Exenatide.
- An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitus.
- A prospective study of concomitant GLP-1 analogue and insulin use in type 2 diabetes in clinical practice.
- Construction of human pluripotent stem cell-derived testicular organoids and their use as humanized testis models for evaluating the effects of semaglutide.
- Efficacy and Safety of GLP-1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity: A Bayesian NMA.
- Pioneering oral peptide therapy for patients with type 2 diabetes.
- Euglycemic Ketoacidosis Following Coadministration of an SGLT2 Inhibitor and Tirzepatide.
- Impact of tirzepatide in a patient with type 1 diabetes and obesity: A case report.
- Exendin-4 attenuates brain death-induced liver damage in the rat.
- Effects of Dulaglutide on Thyroid C Cells and Serum Calcitonin in Male Monkeys.
- Prophylactic effects of the glucagon-like Peptide-1 analog liraglutide on hyperglycemia in a rat model of type 2 diabetes mellitus associated with chronic pancreatitis and obesity.
- Embracing the Pros and Cons of the New Weight Loss Medications (Semaglutide, Tirzepatide, Etc.).
- Switching from Insulin Degludec plus Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide Improves Glycemic Variability in Patients with Type 2 Diabetes: A Preliminary Prospective Observation Study.
- GLP-1 Receptor Agonist Treatment Improves Fasting and Postprandial Lipidomic Profiles Independently of Diabetes and Weight Loss.
- Semaglutide exposure and its association with adverse outcomes in diabetic patients undergoing transforaminal lumbar interbody fusion for lumbar degenerative disc disease.
- Administration of Exendin-4 but not CCK alters lick responses and trial initiation to sucrose and intralipid during brief-access tests.
- Glucagon-like peptide-1 receptors agonists (GLP1 RA).
- Evaluation of the Clinical Efficacy of the Treatment of Overweight and Obesity in Type 2 Diabetes Mellitus by the Telemedicine Management System Based on the Internet of Things Technology.
- Diabetic Kidney Disease - Semaglutide Flows into the Mainstream.
- Sustained exenatide delivery via intracapsular microspheres for improved survival and function of microencapsulated porcine islets.
- Comparison between liraglutide alone and liraglutide in combination with insulin on osteoporotic rats and their effect on bone mineral density.